Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.
about
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursorsProphylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursorsProphylactic human papillomavirus vaccinesVirus-like particles production in green plantsThe causal relation between human papillomavirus and cervical cancer.Characterization of HPV16 L1 loop domains in the formation of a type-specific, conformational epitopeKinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvantLessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteinsCrystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodiesConcatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccinesAgainst which human papillomavirus types shall we vaccinate and screen? The international perspectiveProduction of Furin-Cleaved Papillomavirus Pseudovirions and Their Use for In Vitro Neutralization Assays of L1- or L2-Specific AntibodiesVirus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.Influenza vaccines based on virus-like particlesMF59™ as a vaccine adjuvant: a review of safety and immunogenicity.Prevalence of HPV infection among Greek women attending a gynecological outpatient clinicA replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challengePapillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer.Maturation of papillomavirus capsids.Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.Cost-effectiveness of a potential vaccine for human papillomavirus.Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers.Noninfectious virus-like particle antigen for detection of swine vesicular disease virus antibodies in pigs by enzyme-linked immunosorbent assayViable adenovirus vaccine prototypes: high-level production of a papillomavirus capsid antigen from the major late transcriptional unit.Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women.Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles.Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccineCorrelation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccinationEvaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women.Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity.In vivo mechanisms of vaccine-induced protection against HPV infection.Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial.Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses.Immune responses in macaques to a prototype recombinant adenovirus live oral human papillomavirus 16 vaccine.Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections.Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccineProtective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein.Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions.Epidemiologic studies of a necessary causal risk factor: human papillomavirus infection and cervical neoplasia.
P2860
Q24202048-B4BBA5DE-558F-40FD-B5C3-D808156A6336Q24235373-F1F1BEBE-4674-4824-B24C-8F926198E6CBQ24545449-E0EAB3DC-CAB3-495A-869C-E6022DAF2A46Q24650772-4EFC5C9F-12C4-4A67-86AD-E44EA2F1E567Q24673148-A1BE701F-5B78-4756-85E6-962AE07FCA8DQ24796150-8655BB9A-1186-4DE9-B4F9-9289DE9BDFB6Q24802323-ABC6BCBA-A46B-46CC-B9AC-6A742D7CB1E9Q27013018-ED7E85D3-CF9B-4134-A800-31500FE5E101Q27647874-0B2C9D9E-54C0-496E-A601-F1C2333BC1E0Q28246307-E1BCAE3A-709C-430C-A521-C6A50A2C9EE8Q28267023-3D546CDB-6DE7-4583-BBED-CFA04DFDE467Q28611356-D0F1F60B-63C7-4985-BACC-F9559082AB02Q30359424-D20740C9-B183-4B84-B69B-75A0A29D882AQ30376236-BE4516C3-4F09-47B9-AAD4-7BC2D2194594Q30394545-C888F3A7-1B40-44B9-B010-C17BE49B3EB9Q33531346-FBEEA0E7-F033-46B4-8F5B-DB379AAB2426Q33621078-03F0409C-C4BF-4CC2-9C6D-007925AC7BD1Q33788885-9CE4B1C7-B76E-474C-9F41-FB86A107AA32Q33834872-C98F0035-D058-4B07-BC7E-83378E3F82B8Q33856453-2D6ABA35-3A2E-435A-809A-9BCFC6E58545Q33865463-2BCB2217-664C-40EE-AB20-94E4BFB2965FQ33908917-27F3FD8F-670A-4544-ACF3-E7A7494224BCQ33910754-7DAEE50F-CB96-4C07-8A0C-D5BE693C0B53Q33932258-EF2AE32C-723B-49DC-8628-CBFBA2FB66F4Q33944133-C810B9A3-177D-4B11-AFC4-9EB853599887Q33967624-BE7211E1-9A39-43A5-BAA4-B3D343B6E1E7Q34032367-21978B42-B7AA-4DC0-BAA3-BF7A45680CA8Q34033823-A15AE07A-3B5C-4F0B-B23E-7AF0F95690D8Q34038946-589E552B-4E9D-406A-BAC9-BD686CED3C22Q34078674-5290FFED-BADF-44F5-BF8B-B10499B14EFCQ34125906-DE5517BD-7F00-40FF-B0BA-0B1EDF37730BQ34199560-35E05492-4347-41F2-9A90-A453018D4C54Q34227402-6D3548CA-6E5C-45FC-B695-8E87DC45EC7DQ34260720-C9C8EE87-2935-4A54-AA97-C3D928A80E34Q34267472-E781517C-FA84-44B2-935D-B885D5BBE25CQ34343006-CF02CF51-7E67-4369-A518-B393FB29A315Q34347179-6FB70122-28D1-4B2A-95FF-E239DA185565Q34434903-F7615E31-155D-4812-AC2D-4B8E95269F77Q34507291-7EF53317-C6DA-431B-B0E3-CD94B405E55BQ34532192-67692FBB-F5D0-42AC-8B6F-704B25B769FD
P2860
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Safety and immunogenicity tria ...... 1 virus-like particle vaccine.
@ast
Safety and immunogenicity tria ...... 1 virus-like particle vaccine.
@en
type
label
Safety and immunogenicity tria ...... 1 virus-like particle vaccine.
@ast
Safety and immunogenicity tria ...... 1 virus-like particle vaccine.
@en
prefLabel
Safety and immunogenicity tria ...... 1 virus-like particle vaccine.
@ast
Safety and immunogenicity tria ...... 1 virus-like particle vaccine.
@en
P2093
P356
P1476
Safety and immunogenicity tria ...... 1 virus-like particle vaccine.
@en
P2093
A Hildesheim
B R Murphy
J T Schiller
M J Reynolds
R A Karron
R Robinson
P304
P356
10.1093/JNCI/93.4.284
P407
P577
2001-02-01T00:00:00Z